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Abstract
Background: Endocan was originally described as a dermatan sulfate proteoglycan found freely
circulating in the blood. Endocan expression confers tumorigenic properties to epithelial cell lines
or accelerate the growth of already tumorigenic cells. This molecule is the product of a single gene
composed of 3 exons. Previous data showed that endocan mRNA is subject to alternative splicing
with possible generation of two protein products. In the present study we identified, and
functionally characterized, the alternative spliced product of the endocan gene: the exon 2-deleted
endocan, called endocanΔ2.
Methods: Stable, endocanΔ2-overexpressing cell lines were generated to investigate the biological
activities of this new alternatively spliced product of endocan gene. Tumorigenesis was studied by
inoculating endocan and endocanΔ2 expressing cell lines subcutaneously in SCID mice. Biochemical
properties of endocan and endocanΔ2 were studied after production of recombinant proteins in
various cell lines of human and murine origin.
Results: Our results showed that the exon 2 deletion impairs synthesis of the glycan chain, known
to be involved in the pro-tumoral effect of endocan. EndocanΔ2 did not promote tumor formation
by 293 cells implanted in the skin of severe combined immunodeficient (SCID) mice.
Conclusion: Our results emphasize the key role of the polypeptide sequence encoded by the
exon 2 of endocan gene in tumorigenesis, and suggest that this sequence could be a target for future
therapies against cancer.
Background
Tumor development is a complex multi-step mechanism,
involving not only the tumor cells but also the microenvi-
ronment (or the stroma) supporting them [1]. Crucial
efforts were done to identify the key molecular players
that orchestrate the tumor – stromal cell interactions, the
neo-blood vessel recruitment and extracellular matrix
organization [2-4]. The proteoglycans are major constitu-
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ents of the tumor stroma and the vascular bed and are
present at the cell surface and in the extracellular matrix
[1]. They are constituted of a protein core with one or
more covalently attached glycosaminoglycan (GAG)
chains. Proteoglycans are produced by both tumor cells
and cells from the tumor stroma and can interact with
growth factors, cytokines and integrins regulating their
actions, thereby potentially contributing to tumor growth
and progression [5-11].
Endocan, previously named Endothelial Specific Mole-
cule-1 (ESM-1), a dermatan sulfate proteoglycan which is
found freely circulating in the blood, is specifically
secreted by endothelial cells and is preferentially
expressed in lung and kidney tissues [12-16].
Recently, we have demonstrated that endocan has a tum-
origenic activity. In vivo, 293 cells which express Endocan
induce tumor formation when injected subcutaneously
(s.c.) in SCID mice while they wild type counterparts do
not. Similarly, endocan expression by tumorigenic HT29
adenocarcinoma cell line results in a markedly increase of
the growth rate of the resulting tumors [17]. The tumori-
genic properties of endocan are dependent on glycan
chain but the role of the protein core, and more particu-
larly of a Phenylalanine-rich (F-rich) region situated
between residues F113 and F116, is also critical. Indeed,
glycosylated endocan mutants with point mutations of
the phenylalanine residues 115 and 116 failed to promote
tumor growth in SCID mice [17]. Furthermore, endocan-
mediated tumor formation was also inhibited by treat-
ment with a specific blocking monoclonal antibody
(mAb) targeted close to this region of the endocan protein
core.
Endocan may be a key player in sustaining tumor growth
and recent microarray analyses identified endocan,
among other genes, as being one of the most significant
molecular signatures defining a poor prognosis in breast
[18], lung [19] but also in prostate cancers [20]. We
already reported that endocan levels were markedly
increased in the sera of patients with lung cancer and were
related to tumor invasiveness [17,21].
The endocan gene was cloned by us in 1995. There is a sin-
gle endocan gene localized on chromosome 5 (5q11.2)
which spans 12 kb. The gene is organized into 3 exons
separated by 2 introns. Exon 1 is encoded by 362 bp, exon
2 by 150 bp, and exon 3 by 1560 bp. Exon 1 and a part of
exon 2 encode for an N-terminal cysteine-rich region of
110 amino acids in length. Exon 2 also encodes for the
functionally-defined Phenylalanine-rich (F-rich) region
(113FPFF116). Finally, exon 3 encodes for the C-terminal
region that supports the O-glycanation site on serine 137.
After deletion of the signal peptide, the mature endocan
polypeptide is composed of 165 amino acids and carries
only one GAG chain. Northern blot analysis identified
initially only one mRNA product in human umbilical
vein endothelial cells (HUVEC) [15]. However, RT-PCR
has revealed an alternative spliced form of endocan
mRNA with an internal deletion of 150 bp [22]. We also
observed two distinct translated products of endocan in
lysates from HUVEC suggesting the presence of products
derived from alternative splicing [13]. Alternative splicing
is a major mode of genetic regulation in higher eukaryotes
and spliced variants or isoforms can have different or
opposite physiological roles [23] and can be used as can-
cer biomarkers [24].
In this report, we analyze the tumorigenic effect of
endocanΔ2, the alternatively spliced product of the endo-
can gene which lacks the sequence encoded by the exon
two. Our data shows that the deletion of exon 2- related
amino acid sequence impairs glycanation, endocanΔ2
being a "part time" proteoglycan. We also demonstrate
that endocanΔ2 does not support tumorigenesis.
Methods
Cell culture
Endothelial cells, derived from umbilical vein (HUVEC)
[25], were cultured on fibronectin-coated flasks in RPMI
1640 with 20 % FCS, 2 mM L-glutamine, 10 μg/ml
heparin and 25 μg/ml endothelial cell growth supplement
(Sigma). The 293 cells (ATCC CRL-1573), SV1 (derived
from HUVECs by SV 40 transformation), and 293 Flp-In
cells (Invitrogen) were cultured in DMEM with 10 % FCS
and 2 mM L-glutamine; 100 μg/ml of Zeocin (Invitrogen)
was added for the 293 Flp-In cells. The CHO (ATTC CCL-
61) were cultured in α-MEM supplemented with 10 %
FCS and 2 mM L-glutamine.
RT-PCR and cDNA cloning
Two μg of total RNA isolated by TRIzol® Reagent from
HUVEC, and rat and mouse lungs, were reverse tran-
scribed with M-MLV Reverse transcriptase (Invitrogen).
Rhesus monkey lung cDNA was purchased from BioCat
(Heidelberg, Germany). PCR was performed for 30 cycles
with a 2 min hot start at 92°C, 1 min annealing at 55°C,
and 30 s extension at 65°C with HotMaster Taq Polymer-
ase (Eppendorf, Le Pecq, France). Endocan cDNAs were
amplified with the following forward (S) and reverse (R)
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R2: 5'-TCAGCGCGGATTTAACCATTT-3';
Human and rhesus monkey endocan sequences were
amplified with S1/R1; Mouse endocan with S2/R1; and rat
endocan with S3/R2. For endocan and endocanΔ2 clon-
ing, forward (5'-GAGGCAGCTGGGAAACATGAAG-3')
and reverse (5'-GCCTTCTCTCAGAAATCACAG-3') prim-
ers were chosen to obtain complete reading frames. PCR
products were subcloned in a pcDNA5/FRT vector (Invit-
rogen) and inserted into a pcDNA3.1 (+) vector (Invitro-
gen).
Cell transfection
One μg of endocan-, endocanΔ2-, or control- pcDNA5/
FRT or pcDNA3.1 (+) DNA was transfected using Lipo-
fectamine 2000 (Life Technologies Inc., Cergy-Pontoise,
France) into HEK 293 Flp-In or HEK 293 cells, as recom-
mended by the manufacturer. The pcDNA5/FRT vector
was co-transfected with the pOG44 vector which results in
expression of the Flp recombinase. which mediates a
homologous recombination event between the FRT sites
from the HEK 293 Flp In cell genome and the pcDNA5/
FRT vector. Stable transfected cells were selected using 100
μg/ml hygromycin B for HEK 293 Flp-In cells or 200 μg/
ml G418 and cloned by limit dilution for HEK 293 cells.
Endocan-pcDNA3.1 (+) was transfected into CHO-K1
cells under the same conditions.
Endocan and endocanΔ2 immunoassays
Endocan and endocanΔ2 enzyme-linked immunosorbent
assay (ELISA) were performed as previously described
[13], using the in house anti-endocan MEP14 (IgG2a/K,
capture) and MEC15 (IgG1/K, detection) monoclonal
antibodies. Subsequent incubations with biotin-conju-
gated anti-mouse IgG1 (BD Biosciences- Pharmingen)
and streptavidin-conjugated horseradish peroxidase
(HRP) were followed by revelation with tetramethylben-
zidine (Sigma).
Immunoprecipitation and western blotting
Supernatants and cell lysate samples from 2–3 × 106 cells,
were prepared as previously described [13]. The samples
were run on 15% acrylamide gels and blotted onto nitro-
cellulose membranes (Hybond ECL, Amersham, Saclay,
France). Detection was performed using MEP14 as the pri-
mary antibody probe, followed by affinity-purified, HRP-
conjugated goat anti-mouse antibody (dilution 1:15,000)
(Sigma) and an enhanced chemiluminescence (ECL)
detection kit (Amersham).
Analysis of endocan isoforms
The HEK 293 cell supernatant was passed through a 0.2
cm × 1.3 cm diethylaminoethyl (DEAE)-Sepharose col-
umn (BIO-RAD, Marne la coquette, France) run originally
in 20 mM Tris HCl pH 7.4, 0.15 M NaCl. Bound endocan
was eluted with 20 mM Tris HCl pH 7.4, 1 M NaCl, and
concentrated in a 0.5 ml 30 kilo Daltons (kDa) molecular
weight cut-off Vivaspin concentrator (Vivascience, Han-
nover, Germany). Samples treated with 1 unit/ml chon-
droitinase ABC (Sigma) overnight at 37°C and diluted 1:1
in sodium dodecylsulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) sample buffer without dithiothrei-
tol (DTT) were subjected to PAGE and western blot
analysis. Reduced conditions were obtained by addition
of 0.1 M DTT in samples.
Animal models
One day after receiving 100 μL of anti asialo-GM1 Ab
(Wako Chemicals, Neuss, Germany) intraperitoneally,
SCID mice were injected s.c. with 106 transfected HEK 293
or HEK 293 Flp-In cells resuspended in 200 μL DMEM
without FCS. Presence of a palpable tumor was assessed
once a week, and largest orthogonal diameters were meas-
ured using a Vernier caliper. Tumor volume was estimated
using the formula: V = a*b2/2, where "a" is the largest and
"b" the shortest diameter. Mice were euthanized when
tumor volume reached at most 2 cm3. The protocol was
approved by the local ethics committee and was compli-
ant with the Directive 86/609/EEC on the protection of
animals used for experimental and other scientific pur-
poses.
Tumor samples
We also collected tumor and normal lung samples from
nine patients undergoing surgery for NSCLC. Immedi-
ately after surgical resection, the pathologist sampled both
the tumor and the lung distant from the tumor. Each sam-
ple was immediately frozen at -20°C in TRIzol reagent
(Invitrogen, Cergy Pontoise, France) for later RNA extrac-
tion. Both the protocol and the use of human tissues were
approved by the local ethics committee, and the patients
gave informed consent. Only patients with a clear histo-
logical classification as NSCLC, and without any previous
treatment, were included in the study.
Results
Alternative splicing of the exon 2 of esm1 gene is restricted 
to primate species
Previous results on vascular endothelial growth factor
(VEGF)- and fibroblast growth factor (FGF)-2- stimulated
primary cultures of human capillary endothelial cells
described two endocan-related mRNA species with 150 bp
differences [22]. The 150 bp deletion corresponds to the
deletion of the entire exon 2 (Fig. 1A) (GenBank Acces-
sion Numbers AJ401091 and AJ401092). We show here
that the two alternative spliced products are also
expressed in resting HUVEC (Fig. 1B). The new endocan
mRNA species with the deletion of exon 2 was called
endocanΔ2 (reported by us: GenBank Accession Number
AJ973643). After cloning of the PCR product we observedBMC Cancer 2008, 8:14 http://www.biomedcentral.com/1471-2407/8/14
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that the reading frame was conserved and lead to the same
stop codon. Endocan appeared to be more abundant than
endocanΔ2. The expression of endocanΔ2 was then stud-
ied in mouse, rat and monkey lungs cDNAs. The expres-
sion of endocanΔ2 is observed in primate (human and
monkey) but not in murine (mouse and rat) lungs (Fig.
1B).
The nucleotide sequence of endocan gene predicts that
exon 1 encodes for the first 100 amino acids including the
signal peptide, exon 2 encodes for 50 amino acids and
exon 3 encodes for the last 34 amino acids. Thus, endocan
and endocanΔ2 cDNA predicted translation products of
165 and 115 amino acids, respectively, with same N- and
C-termini (Fig. 2A). This was consistent with immunopre-
cipitation studies from endothelial cell lysates, which
revealed 2 bands at 18 and 14 kDa, the first band corre-
sponding to endocan, the second band was suspected to
correspond to the endocanΔ2 polypeptide (Fig. 2B lanes 1
and 4). This statement was further confirmed when HEK
293 cells transfected by endocanΔ2 cDNA generated spe-
cifically the 14 kDa band (Fig. 2B lane 6), but also other
bands of 26, 38 and 50 kDa disappearing under reducing
conditions. These results indicated that endocanΔ2
mRNA is primate specific, and is efficiently translated in
HUVEC in a 14 kDa protein.
Exon-2 derived sequence is needed for sustaining 
tumorigenesis
We have previously demonstrated that human endocan
promotes tumor growth in a subcutaneous xenograft
SCID-mouse model [17]. Here, we wondered if
endocanΔ2 also exhibited such a tumorigenic activity. We
established by homologous recombination HEK 293 Flp-
In cells expressing endocan (22 ng/24 h/106  cells),
endocanΔ2 (0.2 ng/24 h/106 cells), and then injected 106
cells into the skin of SCID mice. Every mouse that received
endocan expressing HEK 293 Flp-In cells developed a
tumor approaching 1 cm3 in volume by 7 weeks (Fig. 3A).
During the same time, mice receiving either control vector
or endocanΔ2 expressing HEK 293 Flp-In cells developed
smaller tumors measuring 0.15 cm3 and 0.04 cm3 respec-
tively (Fig. 3A). Since the original experiments were per-
formed with HEK 293 cell line and to discard a potential
cell strain effect, a second series of experiments was per-
formed using the HEK 293 cell line. All endocan-express-
ing HEK 293 cells (560 ng/24 h/106 cells) injected into
SCID mice developed tumors by 5 weeks. After 10 weeks,
the tumors grew up to 2 cm3 (Fig. 3B). No tumors were
observed in mice receiving endocanΔ2-HEK 293 cells (18
ng/24 h/106 cells) or the control vector-transfected cells
Endocan and endocanΔ2 translated products Figure 2
Endocan and endocanΔ2 translated products. A: Scheme of 
endocan translation products, deduced from cDNA 
sequences. Exon 1 is represented in grey, exon 2 in white 
and exon 3 in black. The first amino acid of the translated 
products is numbered -19, and the first of the mature trans-
lated products +1. B: Western Blot of cell lysates in non 
reducing conditions. Lane 1: HUVEC; lane 2: endocan-CHO-
K1 cells; lanes 3 and 5: endocan-HEK 293 cells; lane 4: SV1 
cells; lane 6: endocanΔ2-HEK 293 cells. Black arrow indicates 
the endocan translation product and white arrow the 
endocanΔ2 translation product. Stars indicate the multimeric 
forms of endocanΔ2.
Expression of endocan and endocanΔ2 spliced products of  esm1 gene Figure 1
Expression of endocan and endocanΔ2 spliced products of 
esm1 gene. A: Scheme of the cloned human esm1 gene. (Gen-
Bank Accession Numbers AJ401091 and AJ401092). B: RT-
PCR using primers hybridizing with sequences in exon 1 and 
3 of esm1. Lane 1: endocan-HEK 293 cell line, lane 2: 
endocanΔ2-HEK 293 cell line, lane 3: HUVEC, lane 4: mon-
key lung, lane 5: rat lung, lane 6: mouse lung. The numbers to 
the left are molecular sizes in bp. Black arrows represent the 
endocan cDNA and white arrow represents endocanΔ2 
cDNA.BMC Cancer 2008, 8:14 http://www.biomedcentral.com/1471-2407/8/14
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(Fig. 3B). These data indicate that the expression of
endocanΔ2 does not support tumor growth.
Endocan Δ2 is not over expressed in lung tumors
We also investigated if the non- tumorigenic endocan Δ2
is overexpressed in human non small cell lung cancers
(NSCLC). We use the same methodology as in our previ-
ous report [21]. In a series of 9 patients the median rela-
tive expression of endocanΔ2 to PECAM was 1.2
(interquartile range 1.1 to 1.4) while for the full length
endocan it was 2.0 (interquartile range 1.4 to 2.4). Thus,
we confirmed our previous results that there is a differen-
tial regulation of the alternatively spliced form endocan
Δ2 in lung NSCLC [21].
Deletion of exon 2 derived sequence impairs glycanation
The glycan moiety of endocan is known to play important
role in tumorigenesis [17]. We thus enquired if the glyca-
nation of endocanΔ2 is modified compared to that of
endocan. By its glycan, human endocan binds to the
DEAE-Sepharose. The same property was observed for
endocanΔ2 (Fig. 4A). The DEAE-bound endocanΔ2 was
detected at 40 kDa in reducing conditions (Fig. 4B, lane
3). Treatment with chondroitinase ABC induced a shift
from 40 to 14 kDa (Fig. 4B, lane 4), confirming that
endocanΔ2, as well as endocan, is a proteoglycan with a
chondroitin/dermatan sulfate chain. Surprisingly, not all
endocanΔ2 is glycanated and 47.4 % (ranging from 42.9
% to 50.2 %) of endocanΔ2 was recovered in the flow-
through of DEAE-Sepharose (Fig. 4A). This was confirmed
using crude supernatants in non reducing conditions
revealing two additional bands at 14 and 26 kDa below
the glycanated endocanΔ2 spanning from 35 to 70 kDa
(Fig. 4C, lane 3). Thus, the deletion of the exon 2-derived
sequence impairs the glycanation of the endocanΔ2
polypeptide, partially explaining the lack of tumorigenic
activity.
Deletion of exon 2-derived sequence induces 
oligomerisation
The 14, 26 and 35–70 kDa forms of endocanΔ2 from
crude supernatants suggested some conformational vari-
ants of endocanΔ2. First, the glycanated endocanΔ2 at
35–70 kDa (Fig. 4B, lane 7) resulted in a 40 kDa band
under reducing conditions (Fig. 4B, lane 3). Second,
chondroitinase ABC treated-endocanΔ2 revealed, other
bands at approximately 26, 38 and 50 kDa (Fig. 4B, lane
8), in addition to the 14 kDa band, similarly to those
observed in the lysates from endocanΔ2-HEK 293 cell
(Fig. 2B, lane 6). The 14 kDa band is observed under
reducing conditions only (Fig. 4B, lane 4). These results
suggest that the presence of the exon 2-derived sequence
results in a purely monomeric state for endocan, but in its
absence oligomerization of endocanΔ2 is likely to occur,
which may explain at least partially, the lack of tumori-
genic activity of endocanΔ2.
Deletion of exon 2-derived sequence alters protein 
expression
Despite identical cytomegalovirus promoter, signal pep-
tide and N-terminal polypeptide of 81 amino acids, the
respective secretion levels of endocan and endocanΔ2
were quite different. Transient transfection in HEK 293
cells resulted in 7.5 fold less secretion in cell supernatants,
of endocanΔ2 than endocan (Fig. 4D). In addition, HEK
293 cell clones secreted 31 fold less endocanΔ2 than
endocan. In cell lysates, levels of endocanΔ2 are also
lower than for endocan (Fig. 4D), These findings were
also true for other cell lines as HEK 293 Flp In or CHO.
Kinetics of tumor growth Figure 3
Kinetics of tumor growth. A: SCID mice were injected with 
106 Flp-In HEK 293 cells overexpressing endocan (black box), 
endocanΔ2 (white box) or control vector (stars) (n = 8 ani-
mals per group). B: SCID mice were injected with 106 HEK 
293 cells overexpressing endocan (black box), endocanΔ2 
(white box) or control vector (stars) (n = 4 animals per 
group).BMC Cancer 2008, 8:14 http://www.biomedcentral.com/1471-2407/8/14
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Discussion
Cancer is a leading cause of death in developed countries
[26] and increasing efforts are directed towards under-
standing the biology of this disease. Endocan is an
endothelial cell-derived proteoglycan which is overex-
pressed in various cancers [22,27,28]. In vitro as well as in
vivo data demonstrated that endocan has a tumor growth
promoting activity [17]. Moreover in human non small
cell lung cancers endocan seems to reflect tumor ang-
iogenic stimulation, is associated with tumor invasiveness
and is related to patient prognosis. However endocan
gene transcription results in two separate mRNA (endocan
and endocanΔ2) and only the first one was completely
characterized.
In this study, we have characterized the isoform of endo-
can, called endocanΔ2. This isoform was shown to have
the same N- and C-termini as endocan, but was lacking
the 50 amino acids encoded by exon 2. Our results show
that this exon 2 sequence affects protein multimerisation,
the glycanation status and the tumorigenic activity of
endocan.
Initial Northern blots of both HUVEC and human lung
mRNA have shown a unique endocan mRNA band, con-
sistent with the unique 18 kD protein product from endo-
can transfected cells [15]. Subsequently, RT-PCR on
microvascular endothelial cell lines revealed an alterna-
tive spliced form with a 150 bp difference [22]. We
observed that in HUVEC lysates an additional endocan-
related protein of 14 kD was present, which could be
derived from either a specific peptide cleavage or an alter-
native splicing event. This last hypothesis is more plausi-
ble after our observation that two endocan mRNAs with a
150 bp difference were detected in HUVEC. The exon 2 of
the human endocan gene is exactly 150 bp long, which
definitively argues for an alternative splicing of human
endocan gene resulting in a major form with all 3 exons,
i.e. full-length endocan, and a minor form lacking exon 2,
which we called endocanΔ2. This alternative splicing
seems to be a primate-specific event. Despite the same
A: DEAE-sepharose binding property of endocan and endocanΔ2 Figure 4
A: DEAE-sepharose binding property of endocan and endocanΔ2. The crude supernatants (Input) of transiently transfected 
HEK 293 cells with endocan (grey box) or endocanΔ2 (white box) (n = 4). The bound materials were eluted in 1 M NaCl (Elu-
ate). Endocan and endocanΔ2 levels were measured by ELISA (median values with error bars showing the range). B: The elu-
ates from DEAE-Sepharose column were digested overnight with chondroitinase (Ch) ABC. Digested (lanes 2, 4, 6, 8) and 
undigested (lanes 1, 3, 5, 7) samples were analyzed under reducing (lanes 1–4) or nonreducing (lanes 5–8) conditions. Black 
arrow indicates the endocan translation product and white arrow the endocanΔ2 translation product. Stars indicate the mul-
timeric forms of endocanΔ2. C: Western blot analysis of endocan immunoprecipitated from endothelial or transfected cells 
supernatants. Lane 1: HUVEC; lane 2: endocan-HEK 293; lane 3: endocanΔ2-HEK 293. Black arrow indicates the endocan and 
endocanΔ2 translation products. Star indicate the multimeric form of endocanΔ2; Arrowheads indicate the non-specific bands 
originating from the secondary Ab. D. Endocan (grey box) and endocanΔ2 (white box) levels in the supernatant and cell lysate 
of HEK293 cells after 72 hours of culture assessed by ELISA (median, with error bars showing the range, n = 6) **, p = 0.022.BMC Cancer 2008, 8:14 http://www.biomedcentral.com/1471-2407/8/14
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genomic organization with three exons, only one mRNA,
which contains all 3 exons, was observed in mice. We also
show that the endocanΔ2 cDNA is translated into a 14 kD
protein, thus demonstrating that the two bands of 18 and
14 kD in HUVEC represent the translation products of the
two alternatively spliced forms of the endocan gene.
Alternative splicing is a major mode of regulation of the
biological activities and the glycanation of proteins. One
example is represented by CD44, which is a ubiquitous
cell surface adhesion molecule involved in cell-cell and
cell-matrix interactions. CD44 isoforms are derived from
the differential utilization of 10 variable exons (CD44v1-
v10). Variations in the splicing process occur during
tumor progression and may play a major role in tumori-
genesis [29]. Alternative splicing can also change the glyc-
osylation status of a proteoglycan. For example, in
addition to the large diversity of protein isoforms result-
ing from alternative splicing, CD44 can also undergo dif-
ferent post-transcriptional modifications such as N-
glycosylation and O-glycosylation. Many forms of CD44
are glycanated by chondroitin sulfate, however the v3
exon directs glycanation with heparan sulfate. Here we
demonstrated that endocanΔ2 is secreted mostly as a
chondroitin/dermatan sulfate proteoglycan like endocan,
so the loss of exon 2 does not change the specificity of gly-
canation. Surprisingly, we identified endocanΔ2 as a
"part-time" proteoglycan, based on the presence in the
cell supernatants of both non-glycanated and glycanated
forms. The respective tumor-inducing effects of endocan
and endocanΔ2 have been examined in a tumor xenograft
mouse model. The tumorigenic effect of endocan was
clearly confirmed, independently of both the vector and
the subtype of 293 cells used. In contrast, endocanΔ2 does
not promote tumor growth. This result could be explained
by (i) the absence of the exon-2-containing F-rich region,
which is needed for tumorigenesis [17] (ii) the partial lack
of the glycan chain previously shown to play an important
role in the tumor promoting activity of endocan [17], and
(iii) the formation of distinct disulfide-linked oligomers
by endocanΔ2, which might also affect the pro-tumoral
activity by substantial modifications of protein conforma-
tion. Indeed, the deletion of 6 out of the 18 cysteines
present in endocan, as a result of the splicing out of exon
2, may result in a reorganization of the disulfide bonds
that alter the balance between mono- and oligo-meriza-
tion. Some of these changes may also be inter-related in
that a tendency towards protein multimerisation may
restrict glycanation, or vice versa. The low levels of protein
secretion for endocanΔ2 could eventually explain the lack
of its tumorigenic activity. However very low levels of
endocan secretion are necessary to sustain tumor growth
as demonstrated by the tumorigenicity of 293 Flp-In cells
which secrete very low levels of endocan. The secreted lev-
els of endocan Δ2 are higher than the spontaneous secre-
tion of endocan by the 293 Flp-In cells and thus do not
sustain this hypothesis. Whatever the mechanism(s),
these results nevertheless strongly suggest a key role for
the exon 2-derived sequence in the pro-tumorigenic effect
of endocan.
Recently, many microarray and substractive hybridization
analyses of the gene expression profiles in several human
cancers have identified endocan as being one of the genes
defining a tumor signature, associated with poor progno-
sis with an increased risk of death or invasive disease in
melanoma, breast, kidney prostate and lung cancers, [18-
20,28,30]. Interestingly, in human lung cancer, we sug-
gested previously and confirmed in the present paper that
the mRNA of endocan is increased in tumor endothelial
cells, while the mRNA of endocanΔ2 remained
unchanged, indicating a putative regulation of the splic-
ing of the endocan gene [21]. In parallel, we have found
elevated levels of endocan circulating in the blood [21].
Several lines of evidence suggest that endocan expression
normally predominates over endocanΔ2 expression in
vivo. Firstly, the expression of endocanΔ2 mRNA is lower
than that of endocan mRNA in HUVEC and in human
lung tissues; secondly, the non-glycanated endocanΔ2
observed in endocanΔ2–293 cells, was not detected in
immunoprecipitates from HUVEC supernatants; and
thirdly, treatment with chondroitinase ABC did not reveal
the endocanΔ2 protein core in either HUVEC superna-
tants or in normal human serum.
Conclusion
Taken all together, these results show that the alternative
splicing of endocan gene may be one important mecha-
nism that might downregulate the function of endocan.
The presence of an isoform which lacks the tumor pro-
moting effect of endocan implies that in subsequent
molecular biology analyses (microaray or real time PCR)
the choice of the primers should be done very carefully in
order to distinguish only the tumorigenic form. Pro-
teomic analyses should also take into account these differ-
ences if they are done from crude tissues extracts. This
does not apply to the quantification of the circulating
form of endocan. Even if the available ELISA systems
detects both endocan isoforms, the endocanΔ2 is poorly
secreted and accounts only for a very small fraction of the
secreted protein.
In conclusion, we characterized a novel alternatively
spliced product of the endocan gene that is devoided of
tumorigenic activity. Our data strongly suggest that endo-
can exon 2-derived sequence may represent a potential
therapeutic target in human lung cancer.BMC Cancer 2008, 8:14 http://www.biomedcentral.com/1471-2407/8/14
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